Multiple Plantar Warts
Conditions
Interventions
Control group:Placebo capsules + Pingyangmycin
Intervention Group:Selenium Nanoparticles Capsules + Pingyangmycin
Sponsors
Southern Medical University Dermatology Hospital (Guangdong Dermatology Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged between 18 and 75 years (inclusive of boundary values), regardless of gender. 2.Diagnosed with multiple plantar warts (=3 lesions) in accordance with the diagnostic criteria for plantar warts as outlined in the Chinese Clinical Dermatology edited by Zhao Bian. 3.Planned to receive local injection therapy with pingyangmycin. 4.Treatment history: First onset of the condition, or if recurrent, at least 4 weeks have elapsed since the last treatment (e.g., medication, cryotherapy, electrocautery, CO2 laser, photodynamic therapy, superficial X-ray, etc.), and the original lesions have completely healed. 5.Voluntarily sign the informed consent form and agree to comply with the protocol.
Exclusion criteria
Exclusion criteria: 1.Individuals who have used health supplements or medications that increase blood selenium levels within six months prior to signing the informed consent form, or who have a history of residing in Enshi City, Hubei Province. 2.Individuals with allergies to selenium-containing drugs or foods, or allergies to Vitamin C, Shiitake mushrooms, lactose, edible starch, pingyangmycin, or lidocaine, or those with a history of anaphylactic shock. 3.Individuals with acute active infectious diseases requiring treatment at the time of enrollment, including but not limited to pulmonary infections, tuberculosis, or severe skin infections at the planned injection site (e.g., severe redness, swelling, heat, or pain) that make local skin injection temporarily unsuitable. 4.Individuals with severe organic diseases of the liver, kidney, heart, or cerebrovascular system; connective tissue diseases; malignant tumors; or mental disorders. 5.Individuals currently participating in other clinical trials. 6.Women who are pregnant or breastfeeding, or individuals (regardless of gender) who plan to conceive within three months after the trial period and are unwilling to adopt effective non-drug contraceptive measures. 7.Individuals whom the investigator deems unsuitable for participation in the study for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change from baseline in the number of symptomatic days; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient-level complete wart clearance rate;Proportion of responders with = 75% reduction in total wart area and thickness;Time to achieve = 50% reduction in total wart area and thickness;Incidence of recurrent or new events and event-free survival;Dermatology Life Quality Index;Relapse-free survival; | — |
Countries
China
Contacts
Public ContactChen Yangxia;Liu Yinghui
Southern Medical University Dermatology Hospital (Guangdong Dermatology Hospital)
Outcome results
None listed